Drug intelligence / Profile preview

huCART19-IL18

Development stage: Phase 1
Lead developer: University of Pennsylvania
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

huCART19-IL18 is a fourth-generation 4-1BB anti-CD19 chimeric antigen receptor (CAR) T-cell therapy engineered to secrete the pro-inflammatory cytokine interleukin-18 (IL-18). This "armored" CAR T-cell product is designed to enhance antitumor activity against CD19-positive B-cell malignancies, particularly in patients who have failed previous anti-CD19 CAR T-cell therapies. The therapy utilizes an expedited 3-day manufacturing process to limit T-cell exhaustion. huCART19-IL18 has shown promising efficacy in heavily pre-treated patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Other names: armored huCART19-IL18anti-CD19 CAR-IL-18-expressing T lymphocytesanti-CD-19 CAR-IL-18-expressing T lymphocytesanti-CD 19 CAR-IL-18-expressing T lymphocytesautologous anti-CD19 CAR-IL-18-expressing T lymphocytes

Targets

CD19 (B lymphocyte antigen CD19)IL-18R (Interleukin-18 receptor complex)

Beyond the preview

Go deeper on huCART19-IL18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on huCART19-IL18.

Explore the full profile